Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance

• Status: Completed
• Trial end date: 2006-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to placebo in lowering post-meal blood glucose levels in people with pre-diabetes who have high blood sugar levels after meals.

• Phase: Phase 3

Details

• Lead Sponsor: Novartis
• Treatments: Vildagliptin

Criteria

Inclusion Criteria:

• Blood glucose criteria must be met

• Body mass index (BMI) in the range 23-45

Exclusion Criteria:

• Diagnosis of diabetes

• Serious cardiovascular events within the past 6 months

• Use of insulin or any oral antidiabetic agent

• Other protocol-defined exclusion criteria may apply